-
公开(公告)号：US20240229036A9
公开(公告)日：2024-07-11
申请号：US18278498
申请日：2022-02-21
Applicant: KNC LABORATORIES CO., LTD.
Inventor： Masafumi MATSUO , Kazuhiro MAETA
IPC: C12N15/113 , A23K20/153 , A23L33/13 , A61P21/00
CPC classification number: C12N15/1136 , A23K20/153 , A23L33/13 , A61P21/00 , C12N2310/11 , C12N2310/321
Abstract: A method of inhibiting the function of myostatin is provided.
An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target sequence in exon 3 of the myostatin gene and is capable of allowing the expression of a splicing variant of myostatin. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and/or hypertrophy, an agent for increasing muscle mass and/or suppressing muscle weakness, an agent for switching the splicing of the myostatin gene from production of myostatin to production of a splicing variant thereof, an agent for decreasing myostatin signaling, and an anticancer agent, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.-
Patent Agency Ranking
公开(公告)号：US20220220478A1
公开(公告)日：2022-07-14
申请号：US17618177
申请日：2020-06-18
Inventor： Masafumi MATSUO , Kazuhiro MAETA
IPC: C12N15/113 , A23K20/153 , A23L33/13 , A61K31/712 , A61K31/7125 , A61P19/02 , A61P19/08 , A61P21/02
Abstract: A novel method of myostatin inhibition is provided.
An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target site in exon 1 of the myostatin gene and is capable of inhibiting the production of the mRNA of the myostatin gene. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and/or hypertrophy, an agent for increasing muscle mass and/or inhibiting muscle weakness, an agent for inhibiting production of the mRNA of the myostatin gene, and an inhibitor of the function of myostatin, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.-
3.发明申请公开(公告)号：US20220135637A1
公开(公告)日：2022-05-05
申请号：US17435215
申请日：2020-02-26
Inventor： Masafumi MATSUO , Kosuke OKAZAKI , Kazuhiro MAETA
IPC: C07K14/495 , A23L33/18 , A23K20/147
Abstract: A method of inhibiting myostatin signaling via a myostatin splice variant-derived protein is provided. The protein and an expression system thereof are applicable to therapy for diseases in which myostatin is involved.
-
公开(公告)号：US20240132893A1
公开(公告)日：2024-04-25
申请号：US18278498
申请日：2022-02-21
Applicant: KNC LABORATORIES CO., LTD.
Inventor： Masafumi MATSUO , Kazuhiro MAETA
IPC: C12N15/113 , A23K20/153 , A23L33/13 , A61P21/00
CPC classification number: C12N15/1136 , A23K20/153 , A23L33/13 , A61P21/00 , C12N2310/11 , C12N2310/321
Abstract: A method of inhibiting the function of myostatin is provided.
An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target sequence in exon 3 of the myostatin gene and is capable of allowing the expression of a splicing variant of myostatin. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and/or hypertrophy, an agent for increasing muscle mass and/or suppressing muscle weakness, an agent for switching the splicing of the myostatin gene from production of myostatin to production of a splicing variant thereof, an agent for decreasing myostatin signaling, and an anticancer agent, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.-
5.发明公开公开(公告)号：US20230272403A1
公开(公告)日：2023-08-31
申请号：US18016041
申请日：2021-07-19
Inventor： Masafumi MATSUO , Kazuhiro MAETA , Tsuyoshi FUJIHARA , Itaru OKAMOTO , Masahiro NEYA
IPC: C12N15/113 , A61P31/12
CPC classification number: C12N15/1137 , C12Y304/17023 , A61P31/12 , C12N2310/11 , C12N2310/321 , C12N2310/3231 , C12N2320/33
Abstract: An antisense oligonucleotide is provided which induces exon skipping in ACE2 gene. An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target site in exon 18 of angiotensin-converting enzyme 2 gene and is capable of inducing exon skipping in angiotensin-converting enzyme 2 gene. A pharmaceutical drug comprising the antisense oligonucleotide or a salt or a solvate thereof; and an agent for inhibiting the expression of angiotensin-converting enzyme 2 protein and/or for enhancing the expression of soluble angiotensin-converting enzyme 2.
-
6.发明申请公开(公告)号：US20170137810A1
公开(公告)日：2017-05-18
申请号：US15309588
申请日：2015-05-13
Inventor： Masafumi MATSUO , Seiji MATSUDA
IPC: C12N15/113
CPC classification number: C12N15/113 , A61K31/7088 , A61K31/7115 , A61K31/712 , A61K48/00 , C12N2310/111 , C12N2310/314 , C12N2310/321 , C12N2310/3231 , C12N2320/33
Abstract: Insertion of variant exons of CD44 gene of cancer stem cells into its mRNA is inhibited whereupon the cancer stem cells lose their properties so that they are rendered sensitive to anticancer agents and radiation, possibly leading to cancer treatment.A drug for cancer treatment, comprising an antisense oligonucleotide capable of inducing skipping of variant exon(s) of CD44 gene to thereby increase expression of normal CD44 mRNA, a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof. An oligonucleotide of 20-23 bp having the entirety or a part of any one of the nucleotide sequences as shown in SEQ ID NOS: 1 to 19, a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof. A drug for inducing skipping of at least one variant exon selected from the group consisting of variant exons 8, 9 and 10 of CD44 gene, comprising the above-described oligonucleotide, a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof.
-
-
-
-
-
Search Results
6
records
(took 0.013 seconds)
